Featured Research

from universities, journals, and other organizations

New target for treatment of advanced prostate cancer

Date:
July 7, 2010
Source:
University of North Carolina School of Medicine
Summary:
A recent study provides demonstrates that expression of one of a group of genes found only in humans and non-human primates can promote androgen receptor activity in concert with other proteins called coregulators.

In its early stages, prostate cancer requires androgens (hormones that promote the development and maintenance of male sex characteristics) for growth, and current first-line therapies target the receptor for these hormones to slow cancer's development and spread.

Related Articles


However, advanced prostate cancers are often androgen-independent, meaning that androgen-blocking therapies are ineffective.

Scientists aren't sure how this shift occurs as prostate cancer advances. One idea is that prostate cancer cells acquire the ability to make their own androgen. Another says that the androgen receptor that is known to stimulate tumor growth can still be active even when the hormone is not present. Most likely, both are important.

A recent study by UNC researchers, published in the Journal of Biological Chemistry, provides evidence for the second theory, demonstrating that expression of one of a group of genes found only in humans and non-human primates can promote androgen receptor activity in concert with other proteins called coregulators.

One of a group of MAGE genes, so named because they were originally identified in melanoma, called MAGE-11 interacts with another protein, called p300, to provide the cancer cells with a way to enhance androgen receptor signaling and promote tumor growth, even when patients are undergoing androgen deprivation therapy.

According to team leader Elizabeth M. Wilson, PhD, professor of pediatrics and biochemistry and biophysics at UNC-Chapel Hill, "We found that a small portion of the androgen receptor interacts with the MAGE-11 molecule which serves as a bridge to p300, a strong histone modifying enzyme that increases androgen receptor activity. This is exciting because it shows how the cancer cells have developed a way to boost androgen receptor activity, even in the absence or at low levels of the hormone that binds the androgen receptor."

Wilson, who is also a UNC Lineberger member, goes on to explain that understanding this mechanism opens the door to additional targets for new therapies and broader clinical applications of new drugs.

"The MAGE-11 molecule is a promising target for shutting down androgen receptor activity that promotes the growth of cancer cells," she adds.

Other team members include Emily Askew, a recent PhD graduate of the Toxicology Curriculum at UNC, Suxia Bai, PhD, a former post-doctoral fellow in the Wilson laboratory, and Amanda Blackwelder, a research specialist.

The research was supported by grants from the U.S. Department of Defense, the National Institutes of Health and the U.S. Public Health Service.


Story Source:

The above story is based on materials provided by University of North Carolina School of Medicine. Note: Materials may be edited for content and length.


Cite This Page:

University of North Carolina School of Medicine. "New target for treatment of advanced prostate cancer." ScienceDaily. ScienceDaily, 7 July 2010. <www.sciencedaily.com/releases/2010/07/100706171125.htm>.
University of North Carolina School of Medicine. (2010, July 7). New target for treatment of advanced prostate cancer. ScienceDaily. Retrieved December 22, 2014 from www.sciencedaily.com/releases/2010/07/100706171125.htm
University of North Carolina School of Medicine. "New target for treatment of advanced prostate cancer." ScienceDaily. www.sciencedaily.com/releases/2010/07/100706171125.htm (accessed December 22, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, December 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Touch-Free Smart Phone Empowers Mobility-Impaired

Touch-Free Smart Phone Empowers Mobility-Impaired

Reuters - Innovations Video Online (Dec. 21, 2014) A touch-free phone developed in Israel enables the mobility-impaired to operate smart phones with just a movement of the head. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com
Earthworms Provide Cancer-Fighting Bacteria

Earthworms Provide Cancer-Fighting Bacteria

Reuters - Innovations Video Online (Dec. 21, 2014) Polish scientists isolate bacteria from earthworm intestines which they say may be used in antibiotics and cancer treatments. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com
Existing Chemical Compounds Could Revive Failing Antibiotics, Says Danish Scientist

Existing Chemical Compounds Could Revive Failing Antibiotics, Says Danish Scientist

Reuters - Innovations Video Online (Dec. 21, 2014) A team of scientists led by Danish chemist Jorn Christensen says they have isolated two chemical compounds within an existing antipsychotic medication that could be used to help a range of failing antibiotics work against killer bacterial infections, such as Tuberculosis. Jim Drury went to meet him. Video provided by Reuters
Powered by NewsLook.com
Hugging It Out Could Help You Ward Off A Cold

Hugging It Out Could Help You Ward Off A Cold

Newsy (Dec. 21, 2014) Carnegie Mellon researchers found frequent hugs can help people avoid stress-related illnesses. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins